GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Prothena Corporation
Prothena is a biotech company focused on treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Its stock price is highly volatile and driven by clinical trial results in one of the most complex areas of medicine.
Share prices of companies in the market segment - Neuro
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. We classify it in the Neuroscience sector. The chart below illustrates the overall performance of this complex yet important segment.
Broad Market Index - GURU.Markets
Prothena is an Irish biotech company developing antibody-based therapies for the treatment of neurodegenerative and rare diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Prothena shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PRTA - Daily change in the company's share price Prothena Corporation
The volatility of Prothena, a biopharmaceutical company focused on neurodegenerative diseases, reflects the sector's high risks. Change_co is an immediate reaction to clinical trial news. This metric is the basis for analysis of the CNS drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Prothena Corporation plc is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with the dynamics of PRTA, which focuses on neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Prothena is a biopharmaceutical company specializing in drugs for the treatment of neurodegenerative diseases. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Prothena's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Prothena Corporation
Prothena Corporation's year-over-year performance is a story of developing antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its market capitalization fluctuates dramatically over the course of 12 months based on clinical trial data. Partnerships with giants like Roche are key validation of the potential of its scientific platform.
Annual dynamics of market capitalization of the market segment - Neuro
Prothena Corporation plc is a late-stage biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its stock price reflects the enormous potential of its scientific platform and the high risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Prothena is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Prothena Corporation
The performance of Prothena, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its drugs for neurodegenerative diseases, such as Alzheimer's, the success of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Neuro
Prothena is a late-stage biotech company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. The chart below shows the dynamics of the biotech sector, where advances in treating these diseases are among the most anticipated milestones.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Prothena Corporation is a biotech company focused on treating neurodegenerative diseases. Its stock operates in the world of clinical trials. Positive data can trigger explosive growth, while failures can cause a crash, and these events are completely unrelated to the overall stock market. The chart clearly illustrates this specificity.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Prothena Corporation
Prothena Corporation is a biotech company specializing in diseases caused by protein misfolding (such as Alzheimer's disease). Its weekly stock price is highly volatile and depends on the results of clinical trials.
Weekly dynamics of market capitalization of the market segment - Neuro
Prothena, like the entire Alzheimer's biotech sector, is extremely volatile. Weekly stock price movements in this segment often reflect broader scientific breakthroughs or setbacks, which impact investor interest in the entire field. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Prothena Corporation is a biotech company specializing in neurodegenerative diseases. Its shares follow the rhythm of clinical trial news. The chart will show how its weekly performance is detached from overall market trends, driven by its own unique events.
Market capitalization of the company, segment and market as a whole
PRTA - Market capitalization of the company Prothena Corporation
Prothena Corporation's market capitalization is a curve of hope in the fight against neurodegenerative diseases. This biotech company's chart reflects investors' faith in its Alzheimer's and Parkinson's research. Its ups and downs reflect the company's reaction to clinical trial data.
PRTA - Share of the company's market capitalization Prothena Corporation within the market segment - Neuro
Prothena Corporation is a biotech company whose market share is based on its portfolio of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its market capitalization is heavily dependent on clinical trial results.
Market capitalization of the market segment - Neuro
Prothena is tackling diseases like Alzheimer's and Parkinson's. How big is this arena? The chart below is a barometer of the neuroscience pharmaceutical sector. Its volatile dynamics reflect the enormous risks and potential rewards in finding cures for humanity's most complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Prothena Corporation chart illustrates the risks and promises of developing drugs for neurodegenerative diseases. The company's market cap, focused on Alzheimer's and Parkinson's, rises and falls based on clinical trial data. This chart illustrates one of the most complex and capital-intensive areas in biotech.
Book value capitalization of the company, segment and market as a whole
PRTA - Book value capitalization of the company Prothena Corporation
Prothena Corporation's core value lies in its scientific research, but its book value reflects the tangible side of the business: R&D laboratories, drug manufacturing contracts, and financial reserves. The chart below illustrates how the company has grown its physical capital to combat neurodegenerative diseases.
PRTA - Share of the company's book capitalization Prothena Corporation within the market segment - Neuro
Prothena Corporation fights neurodegenerative diseases, and its tangible assets include cutting-edge laboratories and antibody development centers. Potential treatments for Parkinson's and Alzheimer's diseases are being developed within these facilities. The chart shows the share of this science-intensive R&D infrastructure the company controls in its field.
Market segment balance sheet capitalization - Neuro
Prothena is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Prothena focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Prothena's resources include cutting-edge laboratories and R&D centers where antibodies are developed to treat neurodegenerative diseases. The chart below shows how the company built its scientific and physical capital to combat Alzheimer's and Parkinson's diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Prothena Corporation
Prothena is a biotech company with laboratories. Its market valuation is a bet on the success of its Alzheimer's treatment. The chart is a roller coaster of hopes and disappointments associated with clinical trials.
Market to book capitalization ratio in a market segment - Neuro
Prothena is a biotech company specializing in diseases associated with protein misfolding (such as Alzheimer's). Its valuation depends on the success of clinical trials. The chart shows a high premium to its stock, reflecting hopes for a breakthrough.
Market to book capitalization ratio for the market as a whole
Prothena Corporation is a clinical-stage biotech company specializing in diseases caused by protein misfolding (such as Alzheimer's disease). Its valuation is a pure bet on the success of its research. Compared to the average, its market cap reflects investor hopes for a breakthrough in treating these complex diseases.
Debts of the company, segment and market as a whole
PRTA - Company debts Prothena Corporation
Prothena Corporation is a biotech company specializing in diseases associated with protein misfolding, such as Alzheimer's. This chart reflects its financial position. The company funds its expensive and risky clinical trials through partnerships with major pharmaceutical companies and equity capital.
Market segment debts - Neuro
Prothena is a clinical-stage biotech focused on developing antibodies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This is one of the most complex and risky areas in medicine. This chart shows how its debt policy reflects the need to fund lengthy and expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Prothena Corporation
Prothena Corporation is a biotech company focused on treating neurodegenerative diseases. Developing such drugs is a long and expensive process. This chart shows the extent to which the company finances its clinical trials with debt. It helps assess its financial risks and margin of safety for potential success.
Market segment debt to market segment book capitalization - Neuro
Prothena Corporation is a biotech company specializing in the treatment of neurodegenerative diseases such as Parkinson's. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance lengthy and expensive clinical trials in one of the most complex areas of medicine.
Debt to book value of all companies in the market
Prothena Corporation is a biotech company specializing in diseases of the nervous system. Drug development is a long and expensive process. This chart, reflecting the overall debt burden in the market, serves as an indicator of the investment climate. It helps understand how easily companies in this field can attract funding for their clinical trials.
P/E of the company, segment and market as a whole
P/E - Prothena Corporation
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart reflects the high risks and enormous potential in this field. Its dynamics depend entirely on the results of clinical trials, where failures and successes can be stunning.
P/E of the market segment - Neuro
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. This is one of the most complex and in-demand areas in medicine. This chart reflects the average valuation for the neuroscience sector, highlighting investor hopes for a breakthrough in the treatment of these devastating conditions.
P/E of the market as a whole
Prothena is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. Its valuation is a bet on a breakthrough in one of the most complex areas of medicine. It is unrelated to the overall economic trends shown in this chart and depends solely on clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Prothena Corporation
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects the high, yet risky, expectations for its research. The valuation is a bet on a breakthrough in one of the most complex areas of medicine.
%20P%2FE%20Prothena%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Prothena-Corporation&v=1772401664741 "Chart of the company's future (projected) P/E Prothena Corporation")
Future (projected) P/E of the market segment - Neuro
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects the high but risky expectations in this complex field. Comparing forecasts with the sector reveals the market's confidence in its scientific approach to these devastating illnesses.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772401664742 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Prothena Corporation is a biotechnology company specializing in developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This is one of the most complex and risky areas in medicine. This overall risk appetite curve is critical to funding Prothena's long-term and expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772401664745 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Prothena Corporation
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. The company is in clinical trials. This chart reflects R&D expenses, and future profits depend on the success of its drugs in this highly complex area of medicine.
Profit of companies in the market segment - Neuro
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. This is one of the most complex areas in medicine. The sector's profitability chart reflects the enormous risks, but also the potential rewards, associated with finding cures for these devastating diseases.
Overall market profit
Prothena Corporation is a biotechnology company specializing in developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. This is one of the most complex and in-demand areas of medicine. A breakthrough in this field could bring not only enormous social benefits but also colossal economic rewards.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Prothena Corporation
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This schedule reflects the high risks and expectations associated with clinical trials in one of the most complex areas of medicine.
%20profit%20of%20the%20company%20Prothena%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Prothena-Corporation&v=1772401664754 "Graph of future (projected) profit of the company Prothena Corporation")
Future (predicted) profit of companies in the market segment - Neuro
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart shows forecasts for the biopharmaceutical sector, helping to assess the potential of the company's developments in one of the most complex areas of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772401664755 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
The trajectory on this chart shows expectations for a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Prothena's profit forecast hinges on the results of clinical trials of its antibodies. This is a high-risk, but potentially high-reward, bet on a medical breakthrough.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772401664757 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Prothena Corporation
Prothena is a biotech company specializing in nervous system diseases such as Alzheimer's. Its valuation depends almost entirely on the prospects of its developments. This chart shows the value investors attribute to its science, not its current sales, which may be negligible or nonexistent.
P/S market segment - Neuro
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Alzheimer's. Its valuation is dependent on the success of clinical trials. This chart shows the average valuation in the biotech industry, reflecting investor expectations regarding the future commercial potential and revenue from its drugs.
P/S of the market as a whole
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart, showing the average revenue estimate for Prothena, illustrates that its high valuation is based on its enormous market potential and the expectation of successful clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Prothena Corporation
Prothena is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. The company has no commercial products. This chart reflects investor hopes for a breakthrough in this complex field. It shows the estimated likelihood of success for its clinical trials.
%20P%2FS%20Prothena%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Prothena-Corporation&v=1772401664768 "The graph of the company's future (projected) P/S Prothena Corporation")
Future (projected) P/S of the market segment - Neuro
Prothena Corporation is a biopharmaceutical company focused on developing treatments for neurodegenerative and other rare diseases. This chart compares market expectations for its future revenue with other neuroscience companies. The valuation reflects investor confidence in its scientific platform and partnerships with major pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772401664771 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its future depends on the success of clinical trials. A potential breakthrough in this complex area of medicine could create a huge market, which is reflected in long-term expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772401664772 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Prothena Corporation
Prothena Corporation is a biotechnology company focused on developing drugs for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. While in clinical development, its revenue may come from partnerships rather than direct sales, as reflected in this chart.
Sales of companies in the market segment - Neuro
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. Its work is aimed at solving complex medical problems. This chart shows total pharmaceutical sales, demonstrating the scale and potential of the market for drugs for the treatment of central nervous system diseases.
Overall market sales
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. This overall economic activity chart for Prothena is important through the lens of funding. A healthy economy facilitates the influx of capital into risky but potentially breakthrough areas of medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Prothena Corporation
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Future revenue depends on the success of its clinical trials. This chart reflects analyst expectations for the potential of its research in one of the most complex areas of medicine.
%20sales%20of%20the%20company%20Prothena%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Prothena-Corporation&v=1772401664781 "Schedule of future (projected) sales of the company Prothena Corporation")
Future (projected) sales of companies in the market segment - Neuro
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows projected revenues for the entire biotechnology sector. It reflects the overall hopes for breakthroughs in the treatment of complex diseases, which is crucial to Prothena's success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772401664783 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Prothena Corporation is a biotechnology company specializing in developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its valuation is determined by progress in clinical trials. This graph, reflecting the state of the economy, influences the overall funding available to the biotechnology sector, which is critical for long-term, capital-intensive development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772401664786 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Prothena Corporation
Prothena Corporation is a biotech company focused on treating neurodegenerative diseases. This chart reflects its financial performance during lengthy and expensive clinical trials. This metric demonstrates how the company is managing its significant R&D expenditures in anticipation of a breakthrough and future commercial success.
Market segment marginality - Neuro
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart illustrates its operating structure, typical of a biotech with high clinical research costs, and allows for comparison with other companies in this complex field.
Market marginality as a whole
Prothena Corporation is a clinical-stage biotechnology company specializing in developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its future profitability depends on the success of its scientific research. This total market return chart serves as a contrast to the high-risk, high-reward environment, where a single scientific breakthrough can change everything.
Employees in the company, segment and market as a whole
Number of employees in the company Prothena Corporation
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows the company's growing team of scientists. The increase in staff reflects progress in clinical trials and the high expectations placed on its research platform.
Share of the company's employees Prothena Corporation within the market segment - Neuro
This indicator demonstrates Prothena Corporation's focus on neurodegenerative diseases. The company's employees in this complex biotech sector are focused on developing antibodies for the treatment of Alzheimer's and Parkinson's diseases. This team of scientists is dedicated to combating some of the most complex and currently incurable diseases affecting humanity.
Number of employees in the market segment - Neuro
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. This is one of the most complex areas in medicine. This graph illustrates how research-intensive modern neuroscience is, requiring the involvement of top immunologist scientists.
Number of employees in the market as a whole
Prothena Corporation plc is a biotech company specializing in neurodegenerative diseases. Its value is determined by progress in clinical trials, not by the labor market, as shown in this chart. The company is working to solve complex medical problems such as Alzheimer's and Parkinson's diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Prothena Corporation (PRTA)
Prothena is a biotech company specializing in the treatment of neurodegenerative diseases. This chart is a prime example of intellectual capital valuation in biotech. The company's exceptional value per researcher suggests that the market is pricing in the potential success of its research, which could become blockbusters.
%20of%20the%20company%20Prothena%20Corporation%20(PRTA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Prothena-Corporation-PRTA&v=1772401664814 "Chart of market capitalization per employee (in thousands of dollars) of the company Prothena Corporation (PRTA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Prothena Corporation is a biotech company focused on treating neurodegenerative diseases. Its value is derived from its scientific potential. This chart shows how the market values this potential per scientist. A high value is typical for companies whose developments have the potential to change the lives of millions of people.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772401664819 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Prothena Corporation is a clinical-stage biotech company specializing in diseases associated with protein misfolding (such as Alzheimer's disease). This chart shows an extremely high valuation per employee. Investors are evaluating the company's scientific potential and potential breakthroughs in treating serious diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772401664825 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Prothena Corporation (PRTA)
Prothena is a clinical-stage biotech company focused on neurodegenerative diseases (Alzheimer's, Parkinson's). They are developing antibodies. The company has no commercial profit. This chart shows the net loss (R&D costs) per scientist. This is an investment in science with the hopes of a future blockbuster.
%20Chart%20Prothena%20Corporation%20(PRTA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Prothena-Corporation-PRTA&v=1772401664827 "Company Profit Per Employee (in thousands of dollars) Chart Prothena Corporation (PRTA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Prothena Corporation is a biotech company focused on developing antibodies to treat neurodegenerative diseases (such as Parkinson's and Alzheimer's). This research is risky but potentially breakthrough. This chart shows the cash burn per employee during R&D. It serves as a benchmark for assessing the intensity of research investment compared to other biotech companies in this complex field.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772401664832 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Prothena Corporation (PRTA) is a clinical-stage biotech company specializing in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects its enormous R&D expenditures. The company's profit per employee would be deeply negative. It shows how much money the company is burning through on its scientists in the hopes of creating a breakthrough drug that will recoup all costs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772401664836 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Prothena Corporation (PRTA)
Prothena Corporation is a biotechnology company specializing in the development of antibodies for the treatment of neurodegenerative diseases. This chart reflects the company's clinical-stage activity. Revenue per employee is based on partnerships with major pharmaceutical companies, not on sales of its own drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Prothena-Corporation-PRTA&v=1772401664841 "Sales chart per company employee Prothena Corporation (PRTA)")
Sales per employee in the market segment - Neuro
Prothena Corporation is a biotech company specializing in drugs for the treatment of neurodegenerative diseases (e.g., Alzheimer's disease). This chart shows the average revenue per employee in this segment. For a clinical-stage company, this compares to a segment where revenue often depends on development milestones and partnerships.
Sales per employee for the market as a whole
Prothena Corporation is a clinical-stage biotech company specializing in diseases associated with protein misfolding (such as Alzheimer's and Parkinson's). They currently have no products on the market. This figure will be zero, as their scientific team is entirely focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Prothena Corporation (PRTA)
Prothena Corporation is a biotech company specializing in drugs for the treatment of neurodegenerative diseases (Alzheimer's, Parkinson's). The bearish sentiment seen on this chart reflects the extremely high risks in this segment. Bears are betting on clinical trial failure, as the "graveyard" of Alzheimer's treatment failures is vast.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Prothena-Corporation-PRTA&v=1772401664852 "Short Shares Chart for the Company Prothena Corporation (PRTA)")
Shares shorted by market segment - Neuro
Prothena Corporation is a biotech company focused on treating neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows the overall sentiment in the sector. It reflects the immense investor skepticism toward this "valley of death" in biotech, where 99% of drugs fail in clinical trials.
Shares shorted by the overall market
Prothena is a clinical-stage biotech focused on neurodegenerative diseases. Its value is the hope for a future breakthrough. When this market pessimism graph rises, investors are unwilling to hope. They are selling off unprofitable biotechs en masse, like PRTA, whose fate depends on R&D that will pay off years later.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Prothena Corporation (PRTA)
Prothena (PRTA) is an Irish biotech company developing antibodies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to the setbacks that are common in this complex field.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Prothena-Corporation-PRTA&v=1772401664863 "RSI 14 indicator chart for the company's stock Prothena Corporation (PRTA)")
RSI 14 Market Segment - Neuro
Prothena (PRTA) is an Irish biotech company specializing in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart measures the pulse of the Neuroscience sector. It helps distinguish between PRTA's trial-driven performance and overall "overheating" or "overselling" across the biotech sector.
RSI 14 for the overall market
Prothena (PRTA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRTA (Prothena Corporation)
Prothena (PRTA) is a clinical-stage biotech company specializing in neurodegenerative diseases. It is developing antibodies for the treatment of Alzheimer's and Parkinson's diseases. This chart shows the average Wall Street forecast, reflecting analysts' assessments of the clinical data and the chances of success in this highly complex area of medicine.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRTA-Prothena-Corporation&v=1772401664874 "A chart showing analyst consensus forecasts for the expected stock price. PRTA (Prothena Corporation)")
The difference between the consensus estimate and the actual stock price PRTA (Prothena Corporation)
Prothena (PRTA) is a biotech company specializing in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's (in partnership with Roche). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the significant potential analysts see in their complex, yet billion-dollar pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRTA-Prothena-Corporation&v=1772401664878 "A chart showing the difference between the consensus forecast and the actual stock price. PRTA (Prothena Corporation)")
Analyst consensus forecast for stock prices by market segment - Neuro
Prothena is a biotech company attacking the "holy grail" of neurology: Alzheimer's and Parkinson's diseases. Its R&D pipeline is focused on antibodies against "bad" proteins in the brain. This chart shows analysts' overall expectations across the neuroscience sector, reflecting whether experts believe a breakthrough in the treatment of these complex diseases is imminent.
Analysts' consensus forecast for the overall market share price
Prothena Corporation is a biotech company specializing in developing antibodies to treat neurodegenerative diseases, particularly Alzheimer's and Parkinson's. This chart shows overall risk appetite. For Prothena, which operates in one of the most complex and risky areas of medicine, overall market optimism is critical to funding long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Prothena Corporation
Prothena (PRTA) is a clinical-stage biotech focused on the most challenging targets—neurodegenerative diseases (Alzheimer's, Parkinson's). This chart represents a high-risk R&D bet. Its valuation is a lottery ticket: the market's belief that their scientific approach to misfolded proteins will lead to a breakthrough where all others have failed.
AKIMA Market Segment Index - Neuro
Prothena (PRTA) is a clinical-stage biotech focused on neuroscience; the company (a Roche partner) is developing innovative antibodies for the treatment of Parkinson's and Alzheimer's diseases. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this high-risk (Alzheimer's) R&D bet (PRTA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Prothena is a biotech company developing treatments for diseases caused by protein misfolding (amyloidosis, Alzheimer's). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific development with major partners compares to the overall economic trends affecting biotech.
